EL4 (ATCC® TIB-39)

Organism: Mus musculus, mouse  /  Cell Type: T lymphocyte  /  Disease: lymphoma

Organism Mus musculus, mouse
Cell Type T lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease lymphoma
Strain C57BL/6N
Applications
This cell line is a suitable transfection host.
Storage Conditions liquid nitrogen vapor phase
Karyotype modal number = 39
Images
Derivation
EL4 was established from a lymphoma induced in a C57BL mouse by 9,10-dimethyl-1,2-benzanthracene.
Antigen Expression
H-2b; Thy-1.2
Comments
The cells are resistant to 0.1 mM cortisol and sensitive to 20 μg/mL PHA.

A subline (EL4.IL-2, ATCC TIB-181) that produces high levels of interleukin-2 (IL-2, interleukin 2) is available.

A subline (EL4.IL-2, ATCC TIB-40) that is resistant to 0.1 mM 5-bromo-2'-deoxyuridine (BUdR) is available.

A subline (EL4.BU.1.OUAr.1.1, ATCC TIB-41) that is resistant to 0.1 mM 5-bromo-2'-deoxyuridine and 1 mM ouabain is available.

Tested and found negative for ectromelia virus (mousepox).
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: horse serum to a final concentration of 10%.
Subculturing

Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 105 cells/mL and maintain between 1 X 105 and 1 X 106 cells/mL. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product.

Medium Renewal: Every 2 to 3 days

Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
Name of Depositor M Cohn
References

Ralph P. Retention of lymphocyte characteristics by myelomas and theta+-lymphomas: sensitivity to cortisol and phytohemagglutinin. J. Immunol. 110: 1470-1475, 1973. PubMed: 4541304

Old LJ, et al. The G (Gross) leukemia antigen. Cancer Res. 25: 813-819, 1965. PubMed: 4284252

Gorer PA. Studies in antibody response of mice to tumour inoculation. Br. J. Cancer 4: 372-379, 1950. PubMed: 14801344

Herberman RB. Serological analysis of cell surface antigens of tumors induced by murine leukemia virus. J. Natl. Cancer Inst. 48: 265-271, 1972. PubMed: 4119883

Ralph P, Nakoinz I. Inhibitory effects of lectins and lymphocyte mitogens on murine lymphomas and myelomas. J. Natl. Cancer Inst. 51: 883-890, 1973. PubMed: 4542714

Shevach EM, et al. Immunoglobulin and theta-bearing murine leukemias and lymphomas. J. Immunol. 108: 1146-1151, 1972. PubMed: 4112916

Aparicio CL, et al. Correction for label leakage in fluorimetric assays of cell adhesion. BioTechniques 23: 1056-1060, 1997. PubMed: 9421636

Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 57: 3498-3504, 1997. PubMed: 9270019

Basic Documentation
Other Documentation
References

Ralph P. Retention of lymphocyte characteristics by myelomas and theta+-lymphomas: sensitivity to cortisol and phytohemagglutinin. J. Immunol. 110: 1470-1475, 1973. PubMed: 4541304

Old LJ, et al. The G (Gross) leukemia antigen. Cancer Res. 25: 813-819, 1965. PubMed: 4284252

Gorer PA. Studies in antibody response of mice to tumour inoculation. Br. J. Cancer 4: 372-379, 1950. PubMed: 14801344

Herberman RB. Serological analysis of cell surface antigens of tumors induced by murine leukemia virus. J. Natl. Cancer Inst. 48: 265-271, 1972. PubMed: 4119883

Ralph P, Nakoinz I. Inhibitory effects of lectins and lymphocyte mitogens on murine lymphomas and myelomas. J. Natl. Cancer Inst. 51: 883-890, 1973. PubMed: 4542714

Shevach EM, et al. Immunoglobulin and theta-bearing murine leukemias and lymphomas. J. Immunol. 108: 1146-1151, 1972. PubMed: 4112916

Aparicio CL, et al. Correction for label leakage in fluorimetric assays of cell adhesion. BioTechniques 23: 1056-1060, 1997. PubMed: 9421636

Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 57: 3498-3504, 1997. PubMed: 9270019